WallStSmart
KMTS

Kestra Medical Technologies, Ltd. Common Stock

NASDAQ: KMTS · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$28.02
+1.01% today

Updated 2026-08-14

Market cap
$1.34B
P/E ratio
P/S ratio
14.06x
EPS (TTM)
$-2.43
Dividend yield
52W range
$14 – $30
Volume
0.4M

Kestra Medical Technologies, Ltd. Common Stock (KMTS) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item202020212023202420252026
Total assets$7.87M$30.52M$38.66M$45.95M$295.74M$358.46M
Cash & equivalents$5.76M$24.34M$14.81M$8.25M$237.59M$99.71M
Current assets$6.17M$26.20M$18.42M$14.91M$255.33M$222.36M
Total liabilities$4.02M$28.76M$156.23M$255.33M$90.34M$98.81M
Current liabilities$4.02M$6.61M$36.74M$32.97M$37.98M$50.37M
Long-term debt$20.24M$17.32M$42.54M$41.10M$42.65M
Shareholder equity$3.86M$1.77M$-117.58M$-209.38M$205.41M$259.66M
Retained earnings$-135.98M$-170.08M$-312.31M$-406.44M$-520.25M$-651.86M
Accounts receivable$2.11M$2.00M$8.08M$14.54M
Inventory$2.11M$3.29M$6.57M$6.71M
Goodwill

Frequently asked questions

What is Kestra Medical Technologies, Ltd. Common Stock's revenue?

Kestra Medical Technologies, Ltd. Common Stock's trailing twelve-month revenue is $95.13M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is KMTS?

In its most recent fiscal year, KMTS ran a gross margin of 51.37%, an operating margin of -141.64%, and a net margin of -138.35%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does KMTS generate?

KMTS produced $-116.59M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is KMTS's balance sheet healthy?

KMTS holds $99.71M in cash and equivalents against $42.65M in long-term debt, on $259.66M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.